Misty D. Smith

Misty D. Smith, PhD

Academic Information

Departments College of Pharmacy , Research Assistant Professor - Pharmacology & Toxicology , Research Associate Professor - School of Dentistry

Academic Office Information

misty.smith@pharm.utah.edu

Lab

Research Interests

  • Investigating the therapeutic potential of novel compounds, such as cannabidiol
  • Pharmacotherapeutic potential of neuropeptides, endocannabinoids and other novel therapeutics

RESEARCH INTERESTS

Dr. Smith is a behavioral pharmacologist whom serves as a co-investigator in the NIH-sponsored Anticonvulsant Drug Development (ADD) Program in the Department of Pharmacology and Toxicology in the College of Pharmacy. Dr. Smith's current research is investigating the therapeutic potential of novel compounds, such as cannabidiol, for the treatment of epilepsy and its comorbidities and characterizing the drug interactions of cannabidiol with other concomitant therapeutics. Additional related research interests include the pharmacotherapeutic potential of neuropeptides, endocannabinoids and other novel therapeutics in the treatment of chronic pain, substance abuse and other neuropsychiatric conditions. Dr Smith serves as the Director of the Master of Science (MS) Program in Pharmacology and Toxicology with her Co-Director, Dr. Farzana Alam. Dr. Smith also has a joint appointment as a career-track (research) Associate Professor in the Oral Biology, Medicine, and Pathology Section of the School of Dentistry at the University of Utah.

RELATED LINKS

FAR webpage

ADD Program

College of Pharmacy

Education History

Undergraduate Muskingum University
 BS
Doctoral Training University of South Carolina School of Medicine
 PhD

Selected Publications

Journal Article

  1. Smith MD, Woodhead JH, Handy LS, Pruess TH, Vanegas F, Grussendorf E, Grussendorf J, White K, Bulaj K, Krumin RK, Hunt M, Wilcox KS. Preclinical Comparison of Mechanistically Different Antiseizure, Antinociceptive and/or Antidepressant Drugs in a Battery of Rodent Models of Nociceptive and Neuropathic Pain. Neurochem. Res. 2017 May 15. DOI 10.1007/s11064-017-2286-9 [Epub ahead of print] PMID 28508174

  2. Lin Z, Smith MD, Concepcion GP, Haygood MG, Olivera BM, Light A, Schmidt EW. Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products. J Nat Prod. 2017 Jul 26. doi: 10.1021/acs.jnatprod.7b00317. [Epub ahead of print] PubMed PMID: 28745513.

  3. Klein BD, Jacobsen CA, Metcalf CS, Smith MD, Wilcox KS, Hampson AJ, Kehne JH. Evaluation of Cannabidiol in animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP). Neurochem. Res. 2017 May 6. DOI: 10.1007/s11064-017-2287-8 [Epub ahead of print] PMID: 28478594

Book Chapter

  1. Smith MD, CS Metcalf, KS White. Chapter 17, Pharmacotherapy of the Epilepsies. In Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 13th edition, Eds. Brunton, L. L., Knollmann, B. C. & Hilal-Dandan R. (2017). Goodman & Gilman's pharmacological basis of therapeutics. New York: McGraw-Hill.

  2. White HS, Smith MD. Neurotransmitters and Drug Development in Epilepsy. In Advanced Therapy in Epilepsy. Eds. James W. Wheless, L. James Willmore, and Roger A. Brumback. (2009) Sheltoon, Connecticut. People's Medical Publishing House.

  3. Smith, MD, Wilcox, KS and White, HS. Discovery of Antiepileptic Drugs. Neurotherapeutics. 4(1): 12-17. Jan 2007.

  4. White, HS, Smith-Yockman, M., Srivastava, A. and Wilcox, K.S. Therapeutic Assays for the Identification and Characterization of Antiepileptic and Antiepileptogenic Drugs. 2006. In Models of Seizures and Epilepsy. Ed. A. Pitkanen, P.A. Schwartzkroin, and S.L. Moshe. pp.539-549. New York: Elsevier Acad. Press.

    More Selected Publications